December 23, 2011 - 5:18 p.m.
U.S. FDA Accepts New Drug Application for Gilead’s Once-Daily, Single-Tablet Quad HIV Regimen
Printer Friendly Version 
December 20, 2011 - 4:31 p.m.
Gilead Files European Marketing Application for the Quad, a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infection
Printer Friendly Version 
December 15, 2011 - 4:31 p.m.
Gilead Sciences Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Truvada® for Reducing the Risk of Acquiring HIV
Printer Friendly Version 
December 09, 2011 - 8:31 a.m.
Gilead Announces Two-Year Data From Pivotal Phase 3 Study of Elvitegravir, an Integrase Inhibitor for HIV
Printer Friendly Version 
December 08, 2011 - 6:41 a.m.
Gilead Sciences and World Health Organization Establish New Five-Year Initiative to Prevent Deaths from Visceral Leishmaniasis
Printer Friendly Version 
December 06, 2011 - 6:14 p.m.
Gilead Prices $3.7 Billion of Senior Unsecured Notes
Printer Friendly Version 
December 05, 2011 - 8:33 a.m.
Gilead’s Boosting Agent, Cobicistat, Meets 48-Week Primary Objective in Pivotal Phase 3 Study
Printer Friendly Version 
November 28, 2011 - 4:31 p.m.
Gilead Sciences to Present at the 23rd Annual Piper Jaffray Healthcare Conference on Tuesday, November 29
Printer Friendly Version 
November 28, 2011 - 1:01 p.m.
Gilead Receives European Marketing Authorization for Eviplera(R), a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naive Adults
Printer Friendly Version 
November 21, 2011 - 7:02 a.m.
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
Printer Friendly Version 
November 15, 2011 - 4:07 p.m.
Gilead Sciences Finalizes Agreement with Tibotec Pharmaceuticals to Develop and Commercialize a Single-Tablet Regimen of Prezista(R) with Emtriva(R), GS 7340 and Cobicistat
Printer Friendly Version 
November 14, 2011 - 4:31 p.m.
Gilead Sciences to Present at the Lazard Capital Markets 8th Annual Healthcare Conference on Tuesday, November 15
Printer Friendly Version 
November 08, 2011 - 4:32 p.m.
Gilead Sciences to Present at the 2011 Credit Suisse Healthcare Conference on Wednesday, November 9
Printer Friendly Version 
November 07, 2011 - 8:32 a.m.
Gilead Sciences and Cardiovascular Research Foundation Initiate Phase 3 Clinical Trial with Ranolazine in Patients Who Have Undergone PCI with a History of Prior Chronic Angina
Printer Friendly Version 
November 05, 2011 - 9:02 a.m.
Gilead Announces Positive Five-Year Data Showing Effect of Viread(R) on Liver Fibrosis and Cirrhosis Caused by Chronic Hepatitis B
Printer Friendly Version 
October 27, 2011 - 4:14 p.m.
Gilead Sciences Announces Third Quarter 2011 Financial Results
Printer Friendly Version 
October 27, 2011 - 4:08 p.m.
Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet "Quad" HIV Regimen
Printer Friendly Version 
October 26, 2011 - 8:32 a.m.
Bristol-Myers Squibb and Gilead Sciences Announce Licensing Agreement for Development and Commercialization of New Fixed-Dose Combination Pill for People Living with HIV
Printer Friendly Version 
October 24, 2011 - 4:25 p.m.
Gilead and GlobeImmune Announce License and Collaboration Agreement to Develop Therapeutic Vaccine Products for Treatment of Chronic Hepatitis B Infection
Printer Friendly Version 
October 20, 2011 - 4:31 p.m.
Gilead Sciences to Release Third Quarter 2011 Financial Results on Thursday, October 27, 2011
Printer Friendly Version 
October 05, 2011 - 6:26 p.m.
Gilead and Boehringer Ingelheim Sign License Agreement for Novel HIV Non-Catalytic Integrase Inhibitors
Printer Friendly Version 
September 23, 2011 - 7:14 a.m.
European CHMP Adopts Positive Opinion for Eviplera(R), a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infection
Printer Friendly Version 
September 19, 2011 - 4:31 p.m.
Gilead Sciences to Present at the UBS Global Life Sciences Conference on Tuesday, September 20
Printer Friendly Version 
September 04, 2011 - 11:01 a.m.
Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials That Include GS 9190, Pegylated Interferon and Ribavirin, and Another Direct-Acting Antiviral Agent
Printer Friendly Version 
August 31, 2011 - 4:31 p.m.
Gilead Sciences to Present at Baird's 2011 Health Care Conference on Thursday, September 8
Printer Friendly Version 
August 15, 2011 - 8:31 a.m.
Gilead's Investigational Antiretroviral Quad Regimen Meets 48-Week Primary Objective in Pivotal Phase 3 Clinical Study 102
Printer Friendly Version 
August 10, 2011 - 5:03 p.m.
Gilead Sciences Resolves U.S. Food and Drug Administration Warning Letter Related to San Dimas Manufacturing Facility
Printer Friendly Version 
August 10, 2011 - 4:09 p.m.
U.S. Food and Drug Administration Approves Gilead Sciences' Complera(TM), a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naïve Adults
Printer Friendly Version 
August 08, 2011 - 4:15 p.m.
Gilead Sciences to Purchase Biologics Process Research and Clinical Manufacturing Facility from Genentech
Printer Friendly Version 
July 26, 2011 - 4:10 p.m.
Gilead Sciences Announces Second Quarter 2011 Financial Results
Printer Friendly Version 
July 20, 2011 - 10:30 a.m.
Gilead's Investigational Antiretroviral Elvitegravir Once Daily Non-Inferior to Raltegravir Twice Daily at 48 Weeks
Printer Friendly Version 
July 19, 2011 - 4:30 p.m.
Gilead Sciences to Release Second Quarter 2011 Financial Results on Tuesday, July 26, 2011
Printer Friendly Version 
July 12, 2011 - 3:03 a.m.
Gilead Expands Access Program for Medications in Developing World
Printer Friendly Version 
June 28, 2011 - 8:32 a.m.
Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize a New Fixed-Dose Combination of Cobicistat and Prezista(R)
Printer Friendly Version 
June 14, 2011 - 4:30 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
June 13, 2011 - 8:31 a.m.
Gilead Sciences' Executive Vice President Kevin Young Appointed a Commander of the Most Excellent Order of the British Empire
Printer Friendly Version 
June 10, 2011 - 5:08 p.m.
Gilead Sciences Receives Subpoena from U.S. Department of Justice
Printer Friendly Version 
June 08, 2011 - 4:31 p.m.
Gilead Sciences to Present at the 31st Annual William Blair & Company Growth Stock Conference on Wednesday, June 15
Printer Friendly Version 
May 31, 2011 - 5:10 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
May 05, 2011 - 5:45 a.m.
Gilead Extends Its Funding Support for the Gilead Sciences Research Centre at the Institute of Organic Chemistry and Biochemistry in Prague
Printer Friendly Version 
April 29, 2011 - 4:34 p.m.
Gilead Sciences to Present at the Deutsche Bank 36th Annual Health Care Conference on Tuesday, May 3
Printer Friendly Version 
April 27, 2011 - 4:08 p.m.
Gilead Appoints Dr. Muzammil M. Mansuri as Senior Vice President, Research and Development Strategy and Corporate Development
Printer Friendly Version 
April 20, 2011 - 4:06 p.m.
Gilead Sciences Announces First Quarter 2011 Financial Results
Printer Friendly Version 
April 20, 2011 - 8:30 a.m.
Gilead and MicroDose Therapeutx Announce License and Collaboration Agreement to Develop MDT-637 for Treatment of Respiratory Syncytial Virus
Printer Friendly Version 
April 13, 2011 - 4:31 p.m.
Gilead Sciences to Release First Quarter 2011 Financial Results on Wednesday, April 20, 2011
Printer Friendly Version 
March 30, 2011 - 8:30 a.m.
Yale and Gilead Sciences Announce Cancer Research Collaboration
Printer Friendly Version 
March 23, 2011 - 7:53 p.m.
Gilead Prices $1 Billion of Senior Unsecured Notes
Printer Friendly Version 
March 23, 2011 - 9:11 a.m.
Gilead to Offer Senior Notes
Printer Friendly Version 
March 23, 2011 - 8:31 a.m.
Phase III Clinical Trial of Gilead's Investigational Elvitegravir Meets 48-Week Primary Objective
Printer Friendly Version 
March 11, 2011 - 4:15 p.m.
Gilead Recommends Rejection of Mini-Tender Offer By TRC Capital Corporation
Printer Friendly Version 
March 07, 2011 - 4:30 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
March 04, 2011 - 8:32 a.m.
U.S. FDA Removes Warning about Potential Liver Injury from Boxed Warning of Prescribing Information for Gilead's Letairis
Printer Friendly Version 
February 28, 2011 - 4:35 p.m.
Gilead Sciences to Present at the Cowen & Company 31st Annual Health Care Conference on Monday, March 7
Printer Friendly Version 
February 23, 2011 - 4:30 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
February 22, 2011 - 8:31 a.m.
Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million
Printer Friendly Version 
February 10, 2011 - 4:05 p.m.
Gilead Sciences Refiles New Drug Application with the FDA for Single-Tablet Regimen of Truvada(R) and TMC278
Printer Friendly Version 
February 07, 2011 - 5:02 p.m.
Gilead Sciences Announces Notification of ANDA Filing for Tamiflu(R)
Printer Friendly Version 
January 25, 2011 - 4:07 p.m.
Gilead Sciences Receives Refuse to File Notification From U.S. FDA on New Drug Application for Single-Tablet Regimen of Truvada(R) and TMC278
Printer Friendly Version 
January 25, 2011 - 4:07 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2010 Financial Results
Printer Friendly Version 
January 18, 2011 - 4:30 p.m.
Gilead Sciences to Release Fourth Quarter and Year End 2010 Financial Results on Tuesday, January 25, 2011
Printer Friendly Version 
January 06, 2011 - 4:30 p.m.
Gilead Sciences to Present at the 29th Annual JPMorgan Healthcare Conference on Monday, January 10
Printer Friendly Version 
NASDAQ (US Dollar)
$67.49
 Stock is Down 0.34 (0.50%)
Data as of 03/23/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote